Skip to content

Menu
  • USC Stem Cell
  • About
    • Stem Cell FAQs
    • Mission and History
    • California’s Leadership in Stem Cell Research
    • Founding Supporters and Ambassadors
    • Well-being
    • Jobs
  • News & Events
    • News
    • Events
    • Videos
    • Impact Reports and Newsletters
  • Research
    • Department Faculty
    • Eli and Edythe Broad Center Faculty
    • Research Facilities
    • Clinical Translation
    • USC+CHLA Alpha Clinic
    • Translational Research Committee
    • USC Stem Cell Research Oversight Committee (SCRO)
    • Apply to Become Center Faculty
  • Education & Training
    • Undergraduate
    • Master’s Program
    • PhD Program
    • Medical Education
    • Postdoctoral Opportunities
    • Our Trainees
  • Funding
  • Inclusive Excellence
  • Support Us
  • Contact
    • Directory
    • Subscribe
  • Search

Particle shows promise for treating the most deadly type of breast cancer

By  Cristy Lytal

Posted May 18, 2018
Reading Time 2 minutes

in this section

  • News
  • Events
  • Videos
  • Impact Reports and Newsletters

read this next

Rong Lu and Min Yu (Photo by Cristy Lytal)

Min Yu and Rong Lu explore how one bad cell spoils the bunch

  • Follow us on
  • Like us on
  • Follow us on
  • Follow us on
Metastatic breast cancer cells (yellow) interacting with macrophages (magenta) (Image by Oihana Iriondo/Yu Lab)
Metastatic breast cancer cells (yellow) interacting with macrophages (magenta) (Image by Oihana Iriondo/Yu Lab)

USC Stem Cell researchers from the laboratory of Min Yu have positive news for patients with triple-negative breast cancer (TNBC), the most deadly type of breast cancer. By inhibiting a protein called TAK1, postdoc Oihana Iriondo and her colleagues reduced lung metastases in mice with TNBC, as described in a new study in Nature Communications.

In the 20 percent of breast cancer patients with TNBC, it appears that TAK1 enables malignant cells from the breast to survive in the unique environment of the lungs, and form new metastatic tumors. Metastases are the most common cause of cancer-related death.

There’s already a potential drug, called 5Z-7-Oxozeaenol or OXO, that can inhibit TAK1—and presumably make it much more difficult for breast cancer cells to form lung metastases. However, OXO is not stable in the blood, and therefore wouldn’t work in patients.

To overcome this obstacle, Yu and her lab teamed up with the laboratory of Pin Wang at the USC Viterbi School of Engineering. Wang’s team developed a nanoparticle—consisting of a tiny fatty sac—that can effectively carry drugs through the bloodstream and deliver them to tumors.

The scientists loaded this nanoparticle with OXO, and used it to treat mice that had been injected with human breast cancer cells. While OXO did not shrink primary tumors in the breast, the potential drug greatly reduced metastatic tumors in the lungs—with minimal toxic side effects.

“For patients with triple-negative breast cancer, systemic chemotherapies are largely ineffective and highly toxic,” said Yu, an assistant professor of stem cell biology and regenerative medicine, and principal investigator at the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, and the USC Norris Comprehensive Cancer Center. “So nanoparticles are a promising approach for delivering more targeted treatments, such as OXO, to stop the deadly process of metastasis.”

Additional co-authors include Grace Lee, Mostafa Elhodaky, Christian Jimenez, Lin Li, and Julie Lang from the Keck School, and Yarong Liu from USC Viterbi.

Funding came from the National Cancer Institute (K22 CA175228-01A, DP2CA206653, and P30CA014089) and the USC Ming Hsieh Institute for Engineering Medicine for Cancer.

Read more about: Cancer

Post navigation

← 2018 Call for applications: T32 Training Fellowships in Developmental Biology, Stem Cells, and Regeneration
Patt Levitt named inaugural Chief Scientific Officer at CHLA →
Keck School of Medicine of USC
1975 Zonal Ave.
Los Angeles, CA 90033
Google Map
Phone: (323) 442-1900
Hours:
Monday–Friday
7:30am–5:00pm PST
Resources For
  • Current Students
  • Faculty & Staff
  • Patients
  • Community
  • Press
  • Visitors
Areas of Focus
  • Education & Training
  • Research
  • Patient Care
  • Community
Departments and Offices
  • Departments
  • Institutes and Centers
  • Research Programs
  • Administrative Offices
About Keck
  • History
  • Leadership
  • Annual Report
  • Digital Accessibility
Intranet
  • Privacy Notice
  • Notice of Non-Discrimination
  • Smoke-Free Policy

Copyright © 2025 University of Southern California

  • Research
    • Research HomeCutting-edge research drives innovation in healthcare at the Keck School of Medicine
    • Where Research Happens
    • Research Funding
    • Training and Education
    • Researcher Resources
    • Collaborate and Partner
  • Education
    • Education HomeNurturing future healthcare leaders through excellence in education
    • MD Program
    • Residencies and Clinical Fellowships
    • PhD Programs
    • Master’s Programs
    • Professional Programs
    • Post-Doctoral Researchers
    • CME, Certificate & Undergraduate Programs
  • Departments, Institutes & Centers
    • Basic Science and Clinical DepartmentsExploring foundational science and specialized clinical fields
    • Institutes and Centers
    • Research Programs
  • About
    • About the Keck SchoolDiscover the mission, history, and vision of the Keck School of Medicine
    • History
    • Leadership
    • Dean’s Corner
    • Life in Southern California
    • Visit
  • Our Faculty
  • Current Students
  • Newsroom
  • Events Calendar
  • Support the Keck School
  • USC.edu
  • Are you a Patient?